The mechanism of action of this inhibitor may include increasing the accumulation and activation of KIL cells, reducing the tumour accumulation of CXCR2+ MDSCs in mice, or improving the efficacy of T‐cell immunotherapy [81, 82] (Table 2). This evidence concerns the gene CXCR2 and neoplasm.